title: Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life.
abstract: OBJECTIVE
  This study was designed to evaluate the comparative efficacy and safety of sertraline and nortriptyline for the treatment of major depressive disorder in older adults.
  
  
  METHODS
  A double-blind, parallel group design was used to compare 210 outpatients, 60 years of age and older, who met DSM-III-R criteria for major depressive episode and had a minimum Hamilton Depression Rating Scale score of 18. The patients were randomly assigned to 12 weeks of treatment with either sertraline (50-150 mg/day) or nortriptyline (25-100 mg/day).
  
  
  RESULTS
  The safety profiles of the two treatments were similar except that nortriptyline treatment was associated with a significant increase in pulse rate, whereas sertraline was associated with a nonsignificant decrease. Efficacy of both drugs was similar for both treatments at all time points, with 71.6% (N=53 of 74) of the sertraline-treated patients and 61.4% (N=43 of 70) of the nortriptyline-treated patients achieving responder status by week 12. Time to response was also similar, with more than 75% of the improvement in scores on the Hamilton depression scale having occurred by week 6. Secondary efficacy measures (posttreatment measures of cognitive function, memory, and quality of life) revealed a significant advantage for sertraline treatment.
  
  
  CONCLUSIONS
  Primary efficacy measures showed sertraline and nortriptyline to be similarly effective. With secondary outcome measures there was consistent evidence of an advantage for the sertraline-treated group. The clinical impact of these measures on the long-term well-being of elderly depressed patients should be examined in a study of maintenance treatment.
authors.affiliation: Department of Psychiatry, Division of Geriatric Psychiatry, USC School Medicine, Los Angeles, CA 90033, USA. bondaref@hsc.usc.edu
authors.forename: W
authors.initials: W
authors.lastname: Bondareff
authors.forename: M
authors.initials: M
authors.lastname: Alpert
authors.forename: A J
authors.initials: AJ
authors.lastname: Friedhoff
authors.forename: E M
authors.initials: EM
authors.lastname: Richter
authors.forename: C M
authors.initials: CM
authors.lastname: Clary
authors.forename: E
authors.initials: E
authors.lastname: Batzar
mesh_terms: D000367:Age Factors; D017668:Age of Onset; D000368:Aged; D000553:Ambulatory Care; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009661:Nortriptyline / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D009661:Nortriptyline; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline